Search Results - "Duus, Elizabeth"

Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials by Temel, Jennifer S, Dr, Abernethy, Amy P, Prof, Currow, David C, Prof, Friend, John, MD, Duus, Elizabeth M, PhD, Yan, Ying, PhD, Fearon, Kenneth C, Prof

“…Summary Background Patients with advanced cancer frequently experience anorexia and cachexia, which are associated with reduced food intake, altered body…”
Get full text

Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials by Garcia, José M, Dr, Boccia, Ralph V, MD, Graham, Charles D, MD, Yan, Ying, PhD, Duus, Elizabeth Manning, PhD, Allen, Suzan, MS, Friend, John, MD

“…Summary Background Cancer anorexia-cachexia syndrome is associated with increased morbidity and mortality. Anamorelin is an oral ghrelin-receptor agonist with…”
Get full text

Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss by Gelhorn, Heather L., Gries, Katharine S., Speck, Rebecca M., Duus, Elizabeth M., Bourne, Richard K., Aggarwal, Dimple, Cella, David

“…Purpose Comprehensive (qualitative and quantitative) assessments of the 12-item functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia…”
Get full text

Appetite and food intake results from phase I studies of anamorelin by Blum, Robert A., Mair, Stuart, Duus, Elizabeth M.

“…Background Loss of appetite and body weight are potentially devastating, highly prevalent cancer complications. The ghrelin receptor is a mediator of appetite…”
Get full text

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile by Pietra, Claudio, Takeda, Yasuhiro, Tazawa-Ogata, Naoko, Minami, Masashi, Yuanfeng, Xia, Duus, Elizabeth Manning, Northrup, Robert

“…Background Anamorelin HCl (ANAM) is a novel, orally active, ghrelin receptor agonist in clinical development for the treatment of cancer cachexia. We report in…”
Get full text

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer by Chen, Gang, Gupta, Richa, Petrik, Silvia, Laiko, Marina, Leatherman, James M, Asquith, Justin M, Daphtary, Maithili M, Garrett-Mayer, Elizabeth, Davidson, Nancy E, Hirt, Kellie, Berg, Maureen, Uram, Jennifer N, Dauses, Tianna, Fetting, John, Duus, Elizabeth M, Atay-Rosenthal, Saadet, Ye, Xiaobu, Wolff, Antonio C, Stearns, Vered, Jaffee, Elizabeth M, Emens, Leisha A

“…Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccines are bioactive, but limited by disease burden and immune tolerance…”
Get more information

Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects by Jordán, Tamás, Basa-Dénes, Orsolya, Angi, Réka, Orosz, János, Ötvös, Zsolt, Ujhelyi, Andrea, Filipcsei, Genovéva, Molnár, László, Solymosi, Tamás, Glavinas, Hristos, Capone, Dominic, Whitfield, Nicola, McDermott, John, McKenzie, Litza, Shurety, Lauren, Duus, Elizabeth Manning

“…Currently approved formulations of the androgen synthesis inhibitor abiraterone acetate (AA) consist of multiple tablets administered daily in a fasted state…”
Get full text

Effects of strong cytochrome P450 (CYP)3A4 inducers/inhibitors on the pharmacokinetic (PK) profile of anamorelin in healthy volunteers by Duus, Elizabeth, Matson, Mark A., Bernareggi, Alberto

“…Abstract only…”
Get full text

A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial by Martinez, Imanol, Kernan, Kenneth, Piasecki, Piotr, Hamilton, Joelle P., Goh, Chee, Árkosy, Peter, Needleman, Sarah, Ratta, Raffaele, Tadayon, Mehrnaz, Watissée, Marie, Duus, Elizabeth, Dreicer, Robert

“…5052 Background: Abiraterone acetate (AA) is a first-line oral hormone therapy for metastatic prostate cancer (mPC), but the licensed formulation is limited by…”
Get full text

Experience of weight loss and its burden in patients with non-small cell lung cancer: Results of an online survey by Rodriguez, Ana Maria, Duus, Elizabeth M, Friend, John

“…Abstract only 71 Background: The main objectives of this study were to characterize and compare the burden of non-small cell lung cancer (NSCLC) patients who…”
Get full text

Self-reported burden of lung cancer for patients who experienced considerable weight loss vs. those who did not by Rodriguez, Ana Maria, Braverman, Julia, Dasmahapatra, Pronabesh, Duus, Elizabeth M, Friend, John

“…Abstract only…”
Get full text

Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients by Temel, Jennifer S., Bondarde, Shailesh Arjun, Jain, Minish Mahendra, Yan, Ying, Duus, Elizabeth Manning, Allen, Suzan, Mann, William

“…Abstract only 42 Background: Anamorelin HCl (ANA) is an oral ghrelin receptor agonist in development for non-small cell lung cancer (NSCLC)-associated…”
Get full text

Effect of anamorelin/ONO-7643, a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model by Northrup, Robert, Kuroda, Ken, Manning Duus, Elizabeth, Routt Barnes, Sheri, Wiley, Tim, Pietra, Claudio

“…Abstract only e19577 Background: Anamorelin/ONO-7643 is an orally-active ghrelin receptor agonist in development for non-small cell lung cancer (NSCLC)-related…”
Get full text

Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study by Garcia, Jose M, Yan, Ying, Manning-Duus, Elizabeth, Friend, John

Get full text